HIV-1 vectors
US5837512A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 14, 1995 |
| Grant date | Nov 17, 1998 |
| Priority date | — |
| Expiry date | Dec 14, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention pertains to a genetically altered human immunodeficiency virus type 1 (HIV-1) which replicates only in human CD4+ cells that express the Tax protein of Human T-cell Lymphotropic Virus Type I (HTLV-I), wherein the HIV long terminal repeat (LTR) promoter and enhancer sequences (NF-kappa-B and Sp1 binding sites) of the genetically altered human immunodeficiency virus type 1 have been replaced by two copies of the HTLV-I LTR 21 base pair repeat Tax-responsive element (TRE). The present invention also pertains to methods for killing HTLV-1 infected cells in humans with HTLV-1 disease (HTLV-1 tumors and HAM/TSP) with the novel genetically altered human immunodeficiency virus type 1 (HIV-1).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.